• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, November 18, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Task Force Demonstrates Feasibility of Cross-Registry Data Harmonization for Mitochondrial Diseases

by
November 18, 2026
in Health
Reading Time: 2 mins read
0
Task Force Demonstrates Feasibility of Cross-Registry Data Harmonization for Mitochondrial Diseases

Task Force Demonstrates Feasibility of Cross-Registry Data Harmonization for Mitochondrial Diseases

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Preliminary initiatives by the Critical Path Institute’s Primary Mitochondrial Diseases Task Force have demonstrated the feasibility of cross-registry data harmonization to accelerate drug development for primary mitochondrial diseases, according to a white paper published in the Orphanet Journal of Rare Diseases. The authors reported that aligning data dictionaries and distinguishing shared from distinct clinical domains provides a viable pathway to overcome persistent data fragmentation across independent registries.

Primary mitochondrial diseases carry an estimated minimum point prevalence of approximately 1 in 5,000 births worldwide, though exact prevalence figures vary depending on the specific geographical region and population evaluated. Researchers have identified more than 470 causative genes associated with primary mitochondrial diseases.

Despite the substantial prevalence and known genetic drivers, the vast majority of primary mitochondrial diseases continue to lack treatments approved by the Food and Drug Administration. While recent regulatory approvals for Barth syndrome and thymidine kinase 2 deficiency represent notable advances, patients with nearly all other mitochondrial conditions remain dependent on supportive and off-label interventions.

The white paper emphasizes that drug development has encountered repeated clinical trial failures driven by marked disease heterogeneity, small patient enrollment cohorts, and an absence of sensitive, disease-specific assessment tools. Traditional outcome measures have frequently proved inadequate in clinical studies, underscoring an urgent requirement for validated, patient-centered endpoints capable of capturing meaningful clinical changes.

Patient- and clinician-led registries have become essential resources for facilitating rapid participant enrollment and gathering detailed real-world data reflecting patient experiences. However, an evaluation of existing registry platforms revealed substantial misalignment in collected data elements alongside areas of operational overlap, creating significant barriers to cross-study comparability and aggregate analyses.

Established in January 2024 as an unprecedented collaborative effort, the task force aims to establish common data standards and leverage integrated datasets to support trial design and regulatory decision-making. The authors concluded that coordinated data harmonization and cross-sector collaboration are essential to advancing PMD drug development.

Subject of Research: Data harmonization and endpoint development in primary mitochondrial diseases

Article Title: Addressing data fragmentation and drug development barriers in primary mitochondrial diseases: the C-Path Primary Mitochondrial Diseases (PMD) Task Force approach to data harmonization, integration, and endpoint development

Article References: Betourne, A., Bhatnagar, R., Reynolds, E., Walls, R., Weissig, V., Martini-Drew, D., & Zilber, S. (2026). Addressing data fragmentation and drug development barriers in primary mitochondrial diseases: the C-Path Primary Mitochondrial Diseases (PMD) Task Force approach to data harmonization, integration, and endpoint development. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/s13023-026-04625-7

Image Credits: AI Generated

DOI: 10.1186/s13023-026-04625-7

Keywords: primary mitochondrial diseases, Critical Path Institute, PMD Task Force, data harmonization, data integration, endpoint development, data dictionaries, patient registries, clinician-led registries, Barth syndrome, thymidine kinase 2 deficiency, disease heterogeneity, real-world data, genotype-phenotype relationships, rare disease drug development, clinical trial design

News Source: Ophelia Keating. (November 18, 2026). Task Force Demonstrates Feasibility of Cross-Registry Data Harmonization for Mitochondrial Diseases. Scienmag.

Tags: Barth syndromeClinical trial designclinician-led registriesCritical Path Institutedata dictionariesdata harmonizationData Integrationdisease heterogeneityendpoint developmentgenotype-phenotype relationshipspatient registriesPMD Task Forceprimary mitochondrial diseasesrare disease drug developmentReal-world datathymidine kinase 2 deficiency
Share12Tweet7Share2ShareShareShare1

Related Posts

Three-Dimensional Tumor Spheroids Uncover Critical Barriers Limiting Nanoparticle Cancer Theranostics

Three-Dimensional Tumor Spheroids Uncover Critical Barriers Limiting Nanoparticle Cancer Theranostics

November 18, 2026
Steroid Therapy for Posterior Scleritis Unmasks Peripapillary Pachychoroid Syndrome in Clinical Case

Steroid Therapy for Posterior Scleritis Unmasks Peripapillary Pachychoroid Syndrome in Clinical Case

November 18, 2026

Composite Hypertension Indices Outperform Traditional Obesity Metrics in Jilin Study

November 18, 2026

Case Report Describes Suspected Great Auricular Nerve Injury After Jugular Vein Catheterization

November 18, 2026

POPULAR NEWS

  • Survey Reveals Lack of Parental Awareness Regarding Sibling Visitation Policies in PICUs

    Survey Reveals Lack of Parental Awareness Regarding Sibling Visitation Policies in PICUs

    29 shares
    Share 12 Tweet 7
  • Review Details How Circulating Tumor Cells Survive Bloodstream Stresses to Drive Metastasis

    29 shares
    Share 12 Tweet 7
  • Laparoscopic Colectomy Cuts Surgical Site Infection Risk in Obese Adults

    29 shares
    Share 12 Tweet 7
  • Aging-Related Immune Cell Imbalances Linked to Subclinical Coronary Artery Disease

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Numerical Models Show Fibers Boost Polymer-Reinforced Concrete Beam Flexural Performance

Carbon Nanotubes and Alkali Treatment Boost Hemp Composite Fracture Resistance by Eighty Percent

Three-Dimensional Tumor Spheroids Uncover Critical Barriers Limiting Nanoparticle Cancer Theranostics

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.